Boston Scientific Unveils Early Taxus Sales Data; Cordis Looks Long-Term
This article was originally published in The Gray Sheet
Executive Summary
Taxus appears to have bolted out of the gate, based on Boston Scientific's March 22 report that the paclitaxel-eluting stent has achieved about 80% of its low-end sales goal in less than half the time predicted